ALEXANDRA / IMpassion030 aims to assess whether adding the anti-PD-L1 monoclonal antibody atezolizumab to chemotherapy after surgery is better at preventing cancer recurrence, compared to chemotherapy alone in patients with triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is a type of breast cancer that tests negative for three markers: estrogen receptors (ER), progesterone receptors (PR) and human epidermal receptor-2 (HER2), which means that this form of the disease does not respond to hormonal therapy or anti-HER2 treatments.

Patients are randomly assigned to one of the following treatment groups:

• Anti-PD-L1 monoclonal antibody plus chemotherapy
  OR
• Chemotherapy alone

Patients receiving atezolizumab will be treated for one year. The study will compare results between the two treatment groups, looking at the invasive disease-free survival (iDFS), iDFS by PD-L1 and lymph node status, overall survival, safety, patient functioning and health related quality of life [1]

Tumour tissue and blood samples will be collected for biomarker research.

ALEXANDRA / IMpassion030 aims to recruit globally 2,300 women and men who are 18 years and older with non-metastatic operable stage II-III TNBC.

Coordinating partners: Breast International Group (BIG), Alliance Foundation Trials (AFT), Institut Jules Bordet/Clinical Trials Support Unit (IJB/CTSU) and Frontier Science and Technology Research Foundation Inc (FSTRF).

Recruitment opened in August 2018 and study completion is expected 7 years after the first patient recruitment.

International clinical trial involving 21 BIG member groups, and approx. 500 sites in 31 countries: Argentina, Australia, Austria, Belgium, Brazil, China, Czech Republic, Denmark, France, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Mexico, Peru, Poland, Romania, Russia, Singapore, South Korea, Spain, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States of America.

Not at the moment.

Hoffmann-La Roche is the sponsor and funder of the study.

The study was designed by BIG, its academic partners and Roche. This trial is conducted following BIG’s Principles of Research Conduct.

NCT03498716